Opendata, web and dolomites

EbolaVac SIGNED

Development of a Chimpanzee Adenovirus Type 3 Ebolavirus Zaire Vaccine

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 EbolaVac project word cloud

Explore the words cloud of the EbolaVac project. It provides you a very rough idea of what is the project "EbolaVac" about.

true    adults    adenovirus    liberia    standards    percent    centrally    occurred    doubling    innovative    engage    deaths    ebo    booster    stage    vaccination    ebola    logistical    centers    besides    coordinated    reside    pressure    reports    immunological    chad3    evd    safe    requested    frontline    candidate    innovation    ebov    vaccine    estimates    world    accelerate    efforts    maintaining    virus    appropriate    ebolavac    22    guinea    license    zaire    prevention    interventions    first    3431    september    wp4    sierra    wp3    ten    disease    times    7470    west    health    outside    quality    care    switzerland    heavily    containment    lausanne    organization    wp2    outbreak    wp5    effect    data    risk    days    outbreaks    countries    contain    declared    capacity    senegal    assist    children    clinical    march    leone    fatalities    complete    ebolavirus    chimpanzee    evaluation    workers    line    gsk    2014    attempting    august    africa    epidemic    front    total    supporting    reported    time    nigeria   

Project "EbolaVac" data sheet

The following table provides information about the project.

Coordinator
GLAXOSMITHKLINE BIOLOGICALS SA 

Organization address
address: RUE DE L INSTITUT 89
city: RIXENSART
postcode: 1330
website: www.gskbio.com

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Belgium [BE]
 Project website http://www.ebolavac.eu
 Total cost 22˙055˙090 €
 EC max contribution 15˙153˙216 € (69%)
 Programme 1. H2020-EU.3.1. (SOCIETAL CHALLENGES - Health, demographic change and well-being)
 Code Call H2020-Adhoc-2014-20
 Funding Scheme RIA
 Starting year 2014
 Duration (year-month-day) from 2014-10-07   to  2018-04-06

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    GLAXOSMITHKLINE BIOLOGICALS SA BE (RIXENSART) coordinator 14˙103˙135.00
2    THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD UK (OXFORD) participant 942˙581.00
3    BERNHARD-NOCHT-INSTITUT FUER TROPENMEDIZIN DE (HAMBURG) participant 107˙500.00
4    CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS CH (LAUSANNE) participant 0.00

Map

 Project objective

The first Ebolavirus Zaire (EBOV) outbreak of 2014 was declared on 22 March in Guinea. As of 30 September 2014, the World Health Organization (WHO) reports the total number of cases in the current outbreak of Ebola virus disease (EVD) in West Africa at 7470, with 3431 deaths. The US Centers for Disease Control and Prevention states that the number of cases is currently doubling every 20 days and estimates the true number of cases at 2.5 times higher than that reported. Countries that have been affected are Guinea, Liberia, Nigeria, Senegal and Sierra Leone. Ten percent of fatalities have occurred among front line health care workers attempting to contain the epidemic. On 7 August 2014, the WHO requested that GSK “fully engage in WHO-coordinated efforts to test, license and make available safe and effective Ebola interventions” to assist in the control of the outbreak. Taking into account the early stage of development, EbolaVac seeks to accelerate the clinical development of the GSK chimpanzee adenovirus type 3 Ebolavirus Zaire (ChAd3-EBO Z) vaccine candidate to make the vaccine available to frontline health care workers at risk and to be used in the containment of EBOV outbreaks. The project specifically aims to: (i) complete Phase 1 development of the ChAd3-EBO Z vaccine by supporting a clinical study conducted in Lausanne, Switzerland (WP2); (ii) evaluate the ChAd3-EBO Z vaccine in Phase 2 testing on adults and children at established clinical study centers in West Africa outside the current most heavily affected countries of Guinea, Sierra Leone, and Liberia (WP3); (iii) investigate immunological effects of vaccination and the effect of booster vaccination (WP4) and (iv) centrally manage and analyse clinical study data (WP5). Besides using an innovative vaccine technology, much of the innovation of this program will reside in its capacity to implement vaccine evaluation under significant time pressure and complex logistical challenges while maintaining appropriate quality standards.

 Deliverables

List of deliverables.
Web based platform live Websites, patent fillings, videos etc. 2019-04-18 14:34:37
Report on status of posting results in the study registry Documents, reports 2019-04-18 14:34:27
Registration No. of Senegal clinical study in a WHO or ICMJE approved registry Documents, reports 2019-04-18 14:34:30
Registration number of clinical trial in ClinicalTrials.gov and Swiss National Clinical Trials Portal Documents, reports 2019-05-30 11:34:49
Clearances from ethic committees and regulatory authorities Documents, reports 2019-05-30 11:34:48
Clinical study report Documents, reports 2019-04-15 16:23:44

Take a look to the deliverables list in detail:  detailed list of EbolaVac deliverables.

 Publications

year authors and title journal last update
List of publications.
2017 Teresa Lambe, Georgina Bowyer, Katie J Ewer
A review of Phase I trials of Ebola virus vaccines: what can we learn from the race to develop novel vaccines?
published pages: 20160295, ISSN: 0962-8436, DOI: 10.1098/rstb.2016.0295
Philosophical Transactions of the Royal Society B: Biological Sciences 372/1721 2019-07-02

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "EBOLAVAC" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "EBOLAVAC" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.)

BFHA 2020 (2019)

Innovation for better ageing

Read More  

VHFMoDRAD (2019)

Viral Haemorrhagic Fever: Modern Approaches for developing bedside Rapid Diagnostics

Read More  

eHealth Week (2016)

eHealth Week 2016

Read More